Patterns of aspirin use in middle-aged adults: The atherosclerosis risk in communities (ARIC) study

被引:77
作者
Shahar, E
Folsom, AR
Romm, FJ
Bisgard, KM
Metcalf, PA
Crum, L
McGovern, PG
Hutchinson, RG
Heiss, G
机构
[1] WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT FAMILY & COMMUNITY MED, WINSTON SALEM, NC 27103 USA
[2] COLLABORAT STUDIES COORDINATING CTR, CHAPEL HILL, NC USA
[3] KANSAS DEPT HLTH & ENVIRONM, BUR DIS CONTROL, TOPEKA, KS USA
[4] UNIV MISSISSIPPI, MED CTR, DEPT MED, JACKSON, MS 39216 USA
[5] UNIV N CAROLINA, SCH PUBL HLTH, DEPT EPIDEMIOL, CHAPEL HILL, NC USA
关键词
D O I
10.1016/S0002-8703(96)90173-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine correlates of and recent trends in aspirin use in middle-age men and women, we analyzed data from population-based samples selected in four U.S. communities. Aspirin use (during a 2-week period preceding the study examination) was more prevalent in whites than in blacks (30% vs 11%; p < 0.001) and in men than in women among whites (31% vs 28%; p < 0.002) but not blacks (10% in both sexes). In all four race and sex groups, there was a graded positive relation between estimated coronary heart disease (CHD) risk and age-adjusted prevalence of aspirin use. For example, 33% of CHD-free white men who reported diagnoses of hypercholesterolemia and hypertension and had ever smoked reported aspirin use as compared with 25% of their risk factor-free counterparts (p < 0.001). Among men with symptomatic CHD or at high risk for CHD, aspirin use increased by four percentage points between 1987 and 1989 in conjunction with the publication of results from the aspirin primary prevention trials. However, nearly 50% of participants reporting a history of myocardial infarction apparently did not take aspirin regularly.
引用
收藏
页码:915 / 922
页数:8
相关论文
共 37 条
  • [1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [2] [Anonymous], 1988, LANCET, V2, P349
  • [3] [Anonymous], 1988, BRIT MED J, V296, P320
  • [4] [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316
  • [5] [Anonymous], 1982, MINNESOTA CODE RESTI
  • [6] [Anonymous], 1988, NEW ENGL J MED
  • [7] [Anonymous], 1992, J Myocard. Ischemia
  • [8] ARROWSMITH JB, 1987, PEDIATRICS, V79, P858
  • [9] BONHAM GS, 1979, VITAL HLTH STAT SERI, V10, P1
  • [10] CANNER PL, 1983, ISRAEL J MED SCI, V19, P413